ZA200101763B - Crystalline forms of Et02C-CH2-(R)Cgl-Aze-Pab-OH. - Google Patents

Crystalline forms of Et02C-CH2-(R)Cgl-Aze-Pab-OH. Download PDF

Info

Publication number: ZA200101763B
Authority: ZA; South Africa
Prior art keywords: compound; aze; cgl; pab; eto
Prior art date: 1998-09-03

Application number

ZA200101763A

Other languages

English (en)

Inventor

Daniel Edvardsson

Lena Hedstroem

Anita Lundblad

Ursula Pettersson

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-03

Filing date

2001-03-01

Publication date

2002-06-03

2001-03-01 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2002-06-03 Publication of ZA200101763B publication Critical patent/ZA200101763B/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

ZA200101763A 1998-09-03 2001-03-01 Crystalline forms of Et02C-CH2-(R)Cgl-Aze-Pab-OH. ZA200101763B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9802974A SE9802974D0 (sv)	1998-09-03	1998-09-03	New crystalline forms

Publications (1)

Publication Number	Publication Date
ZA200101763B true ZA200101763B (en)	2002-06-03

Family

ID=20412468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200101763A ZA200101763B (en)	1998-09-03	2001-03-01	Crystalline forms of Et02C-CH2-(R)Cgl-Aze-Pab-OH.

Country Status (39)

Country	Link
US (5)	US6225287B1 (zh)
EP (1)	EP1107980B1 (zh)
JP (2)	JP3493341B2 (zh)
KR (1)	KR100629825B1 (zh)
CN (1)	CN1204143C (zh)
AP (1)	AP1520A (zh)
AR (1)	AR029312A1 (zh)
AT (1)	ATE231521T1 (zh)
AU (1)	AU763421B2 (zh)
BG (1)	BG105384A (zh)
BR (1)	BR9913464A (zh)
CA (1)	CA2341259A1 (zh)
CU (1)	CU23015A3 (zh)
CZ (1)	CZ2001775A3 (zh)
DE (1)	DE69905054T2 (zh)
DK (1)	DK1107980T3 (zh)
EA (1)	EA003264B1 (zh)
EE (1)	EE200100135A (zh)
ES (1)	ES2192101T3 (zh)
HK (1)	HK1034721A1 (zh)
HR (1)	HRP20010132B1 (zh)
HU (1)	HUP0104330A2 (zh)
ID (1)	ID28779A (zh)
IL (1)	IL141433A0 (zh)
IS (1)	IS1942B (zh)
MY (1)	MY121394A (zh)
NO (1)	NO20011083L (zh)
NZ (2)	NZ510070A (zh)
OA (1)	OA11908A (zh)
PL (1)	PL346544A1 (zh)
SA (1)	SA99200682B1 (zh)
SE (1)	SE9802974D0 (zh)
SK (1)	SK2802001A3 (zh)
TR (1)	TR200100700T2 (zh)
TW (1)	TWI247013B (zh)
UA (1)	UA66869C2 (zh)
WO (1)	WO2000014110A1 (zh)
YU (1)	YU17301A (zh)
ZA (1)	ZA200101763B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9802974D0 (sv) *	1998-09-03	1998-09-03	Astra Ab	New crystalline forms
SE9900070D0 (sv)	1999-01-13	1999-01-13	Astra Ab	New use
SE9902550D0 (sv)	1999-07-02	1999-07-02	Astra Ab	New crystalline forms
US20020115603A1 (en) *	2000-06-22	2002-08-22	Chiron Corporation	Methods and compositions for the treatment of peripheral artery disease
GB0015981D0 (en) *	2000-06-29	2000-08-23	Glaxo Group Ltd	Novel process for preparing crystalline particles
US7645864B2 (en) *	2000-10-12	2010-01-12	Chugai Seiyaku Kabushiki Kaisha	Erythromycin derivative having novel crystal structures and processes for their production
AR035216A1 (es) *	2000-12-01	2004-05-05	Astrazeneca Ab	Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) *	2000-12-01	2006-10-31	Astrazeneca Ab	Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) *	2001-06-21	2004-02-25	Astrazeneca Ab	Formulacion farmaceutica
DE50310038D1 (de)	2002-03-11	2008-08-07	Curacyte Ag	Hemmstoffe der urokinase, ihre herstellung und verwendung
SE0201661D0 (sv) *	2002-05-31	2002-05-31	Astrazeneca Ab	New salts
SE0201659D0 (sv)	2002-05-31	2002-05-31	Astrazeneca Ab	Modified release pharmaceutical formulation
DE10301300B4 (de)	2003-01-15	2009-07-16	Curacyte Chemistry Gmbh	Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) *	2003-05-27	2010-08-24	Astrazeneca Ab	Modified release pharmaceutical formulation
DE10342108A1 (de) *	2003-09-11	2005-04-14	Curacyte Chemistry Gmbh	Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
WO2005031397A2 (en) *	2003-09-26	2005-04-07	Zetetic Institute	Catoptric and catadioptric imaging systems with pellicle and aperture-array beam-splitters and non-adaptive and adaptive catoptric surfaces
US20050209211A1 (en) *	2004-03-16	2005-09-22	Devalina Law	Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
WO2005091696A1 (fr) *	2004-03-29	2005-10-06	Quanta Display Inc.	Structure a cadres pour module retroeclaire
US7524354B2 (en) *	2005-07-07	2009-04-28	Research Foundation Of State University Of New York	Controlled synthesis of highly monodispersed gold nanoparticles
DE102006050672A1 (de)	2006-10-24	2008-04-30	Curacyte Discovery Gmbh	Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) *	2006-12-06	2008-07-01	Astrazeneca Ab	New crystalline forms
US20090061000A1 (en) *	2007-08-31	2009-03-05	Astrazeneca Ab	Pharmaceutical formulation use 030
EP2062909A1 (en) *	2007-11-21	2009-05-27	SOLVAY (Société Anonyme)	Peptide production and purification process
EP2361572B1 (en) *	2010-02-26	2013-04-17	Biedermann Technologies GmbH & Co. KG	Implant for stabilizing bones or vertebrae
US9550585B2 (en)	2014-06-09	2017-01-24	Space Systems/Loral, Llc	Highly inclined elliptical orbit de-orbit techniques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1075277B (it) *	1977-02-11	1985-04-22	Erba Carlo Spa	Derivati insaturi e epossidici dell'acio 7-acilamido-3-cefem-4-carbossilico e procedimento per la loro preparazione
US4315011A (en) *	1978-07-12	1982-02-09	Richter Gedeon Vegyeszeti Gyar Rt.	1-Alkyl-9-bromohexahydroindolo quinolizium salts and use thereof to increase blood flow
GB2096988B (en) *	1980-11-20	1984-08-01	Beecham Group Ltd	Aromatic hydroxyamines
SE9301916D0 (sv) *	1993-06-03	1993-06-03	Ab Astra	New peptides derivatives
SE504185C2 (sv) *	1994-11-08	1996-12-02	Astra Ab	Lagringsstabil vattenlösning för infusion av trombininhibitorer
TW541316B (en) *	1995-12-21	2003-07-11	Astrazeneca Ab	Prodrugs of thrombin inhibitors
US5830805A (en) *	1996-11-18	1998-11-03	Cornell Research Foundation	Electroless deposition equipment or apparatus and method of performing electroless deposition
SE9802974D0 (sv) *	1998-09-03	1998-09-03	Astra Ab	New crystalline forms

1998
- 1998-09-03 SE SE9802974A patent/SE9802974D0/xx unknown
1999
- 1999-08-24 TW TW088114464A patent/TWI247013B/zh not_active IP Right Cessation
- 1999-09-01 MY MYPI99003779A patent/MY121394A/en unknown
- 1999-09-02 ES ES99968671T patent/ES2192101T3/es not_active Expired - Lifetime
- 1999-09-02 CZ CZ2001775A patent/CZ2001775A3/cs unknown
- 1999-09-02 DK DK99968671T patent/DK1107980T3/da active
- 1999-09-02 AP APAP/P/2001/002078A patent/AP1520A/en active
- 1999-09-02 OA OA00100056A patent/OA11908A/en unknown
- 1999-09-02 AT AT99968671T patent/ATE231521T1/de active
- 1999-09-02 AR ARP990104422A patent/AR029312A1/es unknown
- 1999-09-02 AU AU60147/99A patent/AU763421B2/en not_active Ceased
- 1999-09-02 DE DE69905054T patent/DE69905054T2/de not_active Expired - Lifetime
- 1999-09-02 IL IL14143399A patent/IL141433A0/xx unknown
- 1999-09-02 JP JP2000568867A patent/JP3493341B2/ja not_active Expired - Fee Related
- 1999-09-02 NZ NZ510070A patent/NZ510070A/xx not_active IP Right Cessation
- 1999-09-02 WO PCT/SE1999/001514 patent/WO2000014110A1/en active IP Right Grant
- 1999-09-02 PL PL99346544A patent/PL346544A1/xx not_active Application Discontinuation
- 1999-09-02 EP EP99968671A patent/EP1107980B1/en not_active Expired - Lifetime
- 1999-09-02 CU CU20010061A patent/CU23015A3/es unknown
- 1999-09-02 CA CA002341259A patent/CA2341259A1/en not_active Abandoned
- 1999-09-02 CN CNB998128384A patent/CN1204143C/zh not_active Expired - Fee Related
- 1999-09-02 KR KR1020017002730A patent/KR100629825B1/ko not_active IP Right Cessation
- 1999-09-02 SK SK280-2001A patent/SK2802001A3/sk unknown
- 1999-09-02 YU YU17301A patent/YU17301A/sh unknown
- 1999-09-02 UA UA2001021083A patent/UA66869C2/uk unknown
- 1999-09-02 TR TR2001/00700T patent/TR200100700T2/xx unknown
- 1999-09-02 EA EA200100194A patent/EA003264B1/ru not_active IP Right Cessation
- 1999-09-02 EE EEP200100135A patent/EE200100135A/xx unknown
- 1999-09-02 HU HU0104330A patent/HUP0104330A2/hu unknown
- 1999-09-02 BR BR9913464-0A patent/BR9913464A/pt not_active IP Right Cessation
- 1999-09-02 NZ NZ524486A patent/NZ524486A/en not_active IP Right Cessation
- 1999-09-02 ID IDW20010492A patent/ID28779A/id unknown
- 1999-09-02 US US09/424,770 patent/US6225287B1/en not_active Expired - Fee Related
- 1999-10-18 SA SA99200682A patent/SA99200682B1/ar unknown
2001
- 2001-01-04 US US09/753,655 patent/US6440939B2/en not_active Expired - Fee Related
- 2001-02-23 HR HR20010132A patent/HRP20010132B1/xx not_active IP Right Cessation
- 2001-02-28 IS IS5870A patent/IS1942B/is unknown
- 2001-03-01 ZA ZA200101763A patent/ZA200101763B/en unknown
- 2001-03-02 NO NO20011083A patent/NO20011083L/no not_active Application Discontinuation
- 2001-03-26 BG BG105384A patent/BG105384A/xx unknown
- 2001-08-02 HK HK01105394A patent/HK1034721A1/xx not_active IP Right Cessation
2002
- 2002-05-20 US US10/147,908 patent/US6888007B2/en not_active Expired - Fee Related
2003
- 2003-08-26 JP JP2003300959A patent/JP2004075687A/ja active Pending
2005
- 2005-03-11 US US11/077,210 patent/US20050153901A1/en not_active Abandoned
2006
- 2006-08-22 US US11/507,513 patent/US20060287249A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20011083D0 (no)	2001-03-02
US6888007B2 (en)	2005-05-03
JP2004075687A (ja)	2004-03-11
HUP0104330A2 (hu)	2002-04-29
CZ2001775A3 (cs)	2001-10-17
ES2192101T3 (es)	2003-09-16
PL346544A1 (en)	2002-02-11
AR029312A1 (es)	2003-06-25
DE69905054T2 (de)	2003-11-06
SA99200682B1 (ar)	2006-08-22
CN1325406A (zh)	2001-12-05
UA66869C2 (uk)	2004-06-15
OA11908A (en)	2006-04-10
TWI247013B (en)	2006-01-11
KR20010088795A (ko)	2001-09-28
US20050054579A9 (en)	2005-03-10
US20010023244A1 (en)	2001-09-20
DE69905054D1 (de)	2003-02-27
JP2002524467A (ja)	2002-08-06
US20060287249A1 (en)	2006-12-21
DK1107980T3 (da)	2003-04-22
BG105384A (en)	2001-11-30
KR100629825B1 (ko)	2006-09-29
EE200100135A (et)	2002-06-17
CA2341259A1 (en)	2000-03-16
HK1034721A1 (en)	2001-11-02
CU23015A3 (es)	2005-01-25
CN1204143C (zh)	2005-06-01
TR200100700T2 (tr)	2001-07-23
WO2000014110A1 (en)	2000-03-16
MY121394A (en)	2006-01-28
ID28779A (id)	2001-07-05
YU17301A (sh)	2004-05-12
AP2001002078A0 (en)	2001-03-31
NO20011083L (no)	2001-05-03
US6440939B2 (en)	2002-08-27
US20030017992A1 (en)	2003-01-23
EP1107980A1 (en)	2001-06-20
EP1107980B1 (en)	2003-01-22
EA200100194A1 (ru)	2001-10-22
AP1520A (en)	2005-12-28
NZ510070A (en)	2003-04-29
HRP20010132B1 (en)	2004-06-30
US20050153901A1 (en)	2005-07-14
SK2802001A3 (en)	2001-09-11
US6225287B1 (en)	2001-05-01
AU6014799A (en)	2000-03-27
IL141433A0 (en)	2002-03-10
HRP20010132A2 (en)	2002-02-28
IS5870A (is)	2001-02-28
NZ524486A (en)	2004-10-29
IS1942B (is)	2004-08-13
JP3493341B2 (ja)	2004-02-03
BR9913464A (pt)	2001-06-12
SE9802974D0 (sv)	1998-09-03
ATE231521T1 (de)	2003-02-15
EA003264B1 (ru)	2003-02-27
AU763421B2 (en)	2003-07-24

Publication	Publication Date	Title
US20060287249A1 (en)	2006-12-21	Crystalline forms
AU2011334928B2 (en)	2016-09-01	Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
AU765614B2 (en)	2003-09-25	A substantially crystalline form of melagatran
MXPA01002044A (en)	2001-12-04	CRYSTALLINE FORMS OF EtO2
EP4103560A1 (en)	2022-12-21	Novel salts of nilotinib and polymorphic forms thereof
EP1731502A1 (en)	2006-12-13	Novel crystal of triterpene derivative